

Neurotech Appoints Dr Anthony Filippis as MD/CEO

Neurotech International Limited (ASX: NTI) ('Neurotech', 'NTI' or 'the Company') a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, is pleased to announce the appointment of Dr Anthony Filippis as Managing Director and CEO of Neurotech.

Dr Filippis is the Chief Operating Officer of Percheron Therapeutics (ASX:PER), a clinical stage Australian biotechnology company with an ongoing Phase IIb clinical trial in the rare paediatric disease, Duchenne muscular dystrophy. With 25 years' biotech experience, Anthony is an internationally proven senior business leader with a deep understanding and knowledge of the biotech industry and capital markets. Anthony is a transaction-focused deal maker, having led and completed several partnering (in and out-licensing), M&A transactions with pharmaceutical and biotech companies. Throughout his career, he has raised capital and closed many deals, including with blue-chip companies Siemens Healthineers, AstraZeneca, Schering Plough (acquired by Merck), and Mediatech (acquired by Alchemia).

Prior to commencing at Percheron Therapeutics in November 2022, Anthony was CEO & Managing Director of Neurosciences Victoria Limited (NSV) for five and half years and before that CEO of neuroscience drug development company Drawbridge Pharmaceuticals for four years. Anthony is a Founder of Senz Oncology and a Non-Executive Director on the Board of Directors of VivaZome Therapeutics and Connectivity Limited, and is a member of its Finance, Risk and Audit Committee. He is Chairman of the Commercialisation Committee of the Australian Stroke Alliance and a member of its Risk & Work, Health and Safety Committee.

Mr Mark Davies, Chairman of Neurotech said "Following an extensive search of potential candidates for the role, we are delighted that someone of the calibre of Anthony has agreed to join the Company as Managing Director and CEO, commencing 1 February 2025. Anthony will bring to Neurotech a significant amount of experience across the life sciences sector, with an outstanding track record of partnering success and capital markets expertise. On behalf of the Board, we welcome Anthony to the role and look forward to his contribution in executing our NTI164 strategy in 2025, which is shaping up as an important year of delivery for Neurotech as we accelerate our regulatory development."

Commenting on his appointment, Dr Filippis said "I am delighted to join Neurotech at this very important time in the Company's development. With an exciting pipeline and an excellent team of clinical collaborators, I look forward to working with the Board and the team to bring NTI164 forward to provide new treatment options for patients".

The material terms of Dr Filippis' appointment consistent with ASX Listing Rule 3.16.4 are shown in Appendix 1.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0) 402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC ($M<0.3\%$) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

Appendix 1 – CEO/MD Key Terms

Commencement Date as Managing Director and CEO	1 February 2025
Term	No fixed term, ongoing until terminated by either party in accordance with the executive service agreement between the Company and Dr Filippis.
Position	Full time
Services	Dr Filippis has been engaged to provide those services usually required of a Managing Director / Chief Executive Officer of a Company of the scale and nature of Neurotech International Limited, including the overall management of the Company.
Fixed Remuneration	\$468,300 per annum (inclusive of superannuation).
Short Term Incentives	The Company may invite the Executive to participate in a short term incentive plan, and may make a cash payment to the Executive pursuant to that plan subject to the Executive first fulfilling relevant key performance indicators determined by the Board.
Long Term Incentives	It is proposed that the Company will issue the following securities to Dr Filippis (or his nominee) as an equity incentive to his remuneration package: • 5,000,000 Tranche 1 options, with an exercise price of \$0.16 per option¹ • 5,000,000 Tranche 2 options, with an exercise price of \$0.16 per option² • 5,000,000 Tranche 3 options, with an exercise price of \$0.18 per option³ • 5,000,000 Tranche 4 options, with an exercise price of \$0.18 per option⁴ All options are subject to vesting conditions as detailed below. All options have an expiry date of the earlier of 5.00pm (AWST) on the fifth anniversary of the date on which the Option was first issued or 5.00pm (AWST) on the third anniversary of the date on which the Option vested.

Notice Period	Either party may terminate the employment contract by providing 4 months' notice.
-----------------------------	--

1. vest on the first anniversary of the Commencement Date.
2. vest upon 18 month period of continuous service in the position from the Commencement Date and the Company filing a market registration application (which is approved by the Board) for NTI164 with the appropriate health regulator in any one of the following markets: Australia, United States of America, European Union, United Kingdom or the Republic of Korea.
3. vest upon 24 month period of continuous service in the Position, commencing upon the Commencement Date and Neurotech enters into and completes a legally binding licensing transaction and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$200 million for at least 10 consecutive trading days.
4. vest upon 24 month period of continuous service and the Company announcing to the ASX the receipt by the Company of proceeds from the Company's first commercial sale of NTI164 in any market following regulatory approval by the appropriate health regulator, (but not including the sale of NTI164 through any special access scheme or authorised prescriber pathway in Australia or in any other market) and the Company achieving, after the Commencement Date, an Undiluted Market Capitalisation of at least \$300 million for at least 10 consecutive trading days.